July 2, 2021 -- Unchained Labs has launched a new application suite for the characterization of nanoparticles on Stunner, the company's gene therapy platform.
Stunner simultaneously quantifies nanoparticle payloads and measures their size distribution, two critical qualities necessary for an effective nanoparticle vaccine or gene therapy, Unchained said. Moreover, it uses only 2 µL of each sample and performs label-free.
Currently, Stunner provides a method for adeno-associated viruses (AAV) titer and empty/full ratio measurements.